← Evidence map

ReviewCancers2026

PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Agnieszka Gąsowska-Bodnar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | OpenQuestion